reviewDiabetes CareApr 30, 2024BRONZE OA

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?

JCJoão Carlos LocatelliJGJuliene Gonçalves CostaAHAndrew HaynesLHLouise H. NaylorPGP. Gerry Fegan

The University of Western Australia · Curtin University · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in combination with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15-24% weight loss in adults with overweight and…

Citation impact

110
total citations
FWCI
44.22
Percentile
100%
References
94
Citations per year

Authors

7

Topics & keywords

Topics
Keywords
  • Medicine
  • Pharmacotherapy
  • Incretin
  • Diabetes mellitus
  • Weight loss
  • Insulin resistance
  • Internal medicine
  • Endocrinology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding